News

Savara Pharmaceuticals recently announced that it has closed a $20 million Series C financing round, which will be used to advance a pivotal Phase 3 clinical trial of AeroVanc (vancomycin hydrochloride inhalation powder), the first dry powder inhaled antibiotic being developed for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis…

Vertex Pharmaceuticals, Inc.  recently announced that 18 nonprofit groups were chosen to receive Cystic Fibrosis (CF) Circle of Care grants for 2016, totaling nearly $1 million. The award, now in its second year, is given to medical, academic, patient, and community organizations aiding the cystic fibrosis (CF) community. Despite recent…

As part of the annual “March on the Hill” event in Washington, D.C., sponsored by the Cystic Fibrosis Foundation, Texas volunteers joined other advocates from across the U.S. to present Rep. Lloyd Doggett with the Legislative Champion Award for his efforts on behalf of the cystic fibrosis (CF) community. Congressman Doggett,…

The era of classic stethoscopes might soon come to an end, opening the way for digital substitutes — like the one scientists created and linked to a computer program, enabling it to recognize and analyze lung sounds necessary to diagnose and investigate diseases such as cystic fibrosis or chronic obstructive pulmonary disease (COPD). The…

Many people make a bucket list, a wish list of “musts” to see and do before they die. But how many are tucked away in a drawer, and left forgotten? Meet Sandi Alvaro, a young West Virginian who has lived with cystic fibrosis (CF) her entire life and is out…

Austin, Texas-based International Biophysics Corporation, maker of AffloVest — a completely self-contained, battery operated, portable high-frequency chest wall oscillation (HFCWO) device for bringing critical therapy to people struggling with cystic fibrosis (CF), bronchiectasis, and other respiratory diseases — is joining several major U.S.

Hepatopulmonary syndrome (HPS), a liver-induced lung disorder, may be underdiagnosed in at-risk patients with cystic fibrosis (CF), according to a study titled “Hepatopulmonary Syndrome in Patients With Cystic Fibrosis and Liver Disease,” published in the journal Chest. Cystic fibrosis-associated liver disease (CFLD) is the third cause of mortality among…

XENiOS, a privately held medical device company specializing in minimally invasive lung-and-heart assistance, recently announced it has invested $2.6 million in  XOR-Labs Toronto, a spin-off of Toronto General Hospital at University Health Network (UHN) that is working to make more donor lungs available to patients needing transplants because of injuries…

A new study suggests a method for correcting and improving stem cells derived from people with cystic fibrosis (CF), one that could lead to new ways of treating CF using a patient’s own cells. The report, titled “Robust method for TALEN-edited correction of pF508del in patient-specific induced pluripotent stem cells,“ appeared…

Nivalis Therapeutics, Inc., recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational drug, N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, as a potential treatment for patients with cystic fibrosis (CF). The drug is now being evaluated in…